Major depression induces oxidative stress and platelet hyperaggregability

Journal of Psychiatric Research

Volumn 61, Issue , 2015, Pages 19-24

  Ormonde do Carmo, Monique B O ^a   Mendes Ribeiro, AntÔnio Cláudio ^a,b   Matsuura, Cristiane ^a   Pinto, Vivian L ^a   Mury, Wanda V ^a   Pinto, Nathalia O ^a   Moss, Monique B ^a,b   Ferraz, Marcos Rochedo ^a   Brunini, Tatiana M C ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

Arginase; CGMP; CVD; GPx; Major depression; MD; Nitric oxide; NO; NOS; Oxidative stress; PDE5; Platelets; RBC; ROS; SGC; SOD

Indexed keywords

ARGINASE; ARGINASE II; ARGININE; CATALASE; CYCLIC GMP; GLUTATHIONE PEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ARGINASE II, HUMAN; PHOSPHODIESTERASE V INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; BLOOD; CASE CONTROL STUDY; METABOLISM; THROMBOCYTE; YOUNG ADULT;

ADULT; ARGINASE; BLOOD PLATELETS; CASE-CONTROL STUDIES; CATALASE; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; PLATELET AGGREGATION; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84921546561     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.12.009     Document Type: Article

References (32)

1. Amorim P. Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Psiquiatr Clínica 2000, 22:106-115.
2. Bachetti T., Comini L., Francolini G., Bastianon D., Valetti B., Cadei M., et al. Arginase pathway in human endothelial cells in pathophysiological conditions. JMol Cell Cardiol 2004, 37:515-523.
3. Baghai T.C., Varallo-Bedarida G., Born C., Hafner S., Schule C., Eser D., et al. Major depressive disorder is associated with cardiovascular risk factors and low Omega-3 Index. JClin Psychiatry 2011, 72:1242-1247.
4. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313.
5. Berkels R., Klotz T., Sticht G., Englemann U., Klaus W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. JCardiovasc Pharmacol 2001, 37:413-421.
6. Brown A.D., Barton D.A., Lambert G.W. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs 2009, 23:583-602.
7. Brunini T.M., Mendes-Ribeiro A.C., Ellory J.C., Mann G.E. Platelet nitric oxide synthesis in uremia and malnutrition: a role for l-arginine supplementation in vascular protection?. Cardiovasc Res 2007, 73:359-367.
8. Celano C.M., Huffman J.C. Depression and cardiac disease: a review. Cardiol Rev 2011, 19:130-142.
9. Chrapko W., Jurasz P., Radomski M.W., Archer S.L., Newman S.C., Baker G., et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006, 31:1286-1293.
10. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., Le Melledo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004, 56:129-134.
11. Cudney L.E., Sassi R.B., Behr G.A., Streiner D.L., Minuzzi L., Moreira J.C., et al. Alterations in circadian rhythms are associated with increased lipid peroxidation in females with bipolar disorder. Int J Neuropsychopharmacol 2014, 17:1-8.
12. Elgun S., Kumbasar H. Increased serum arginase activity in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:227-232.
13. Fontoura P.C.S., Pinto V.L., Matsuura C., Cheniaux E., Ferraz M.R., Brunini T.M., et al. Defective nitric Oxide/cGMP signaling in bipolar patients: a potential role for platelet dysfunction. Psychosom Med 2012, 74:873-877.
14. Forte A., Hellstrand P., Nilsson B.O., Grossi M., Rossi F., Cipollaro M. The polyamine pathway as a potential target for vascular diseases: focus on restenosis. Curr Vasc Pharmacol 2011, 9:706-714.
15. Franchi F., Angiolillo D.J. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015, 12:30-47.
16. Hallback I., Hagg S., Eriksson A.C., Whiss P.A. Invitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacol Rep 2012, 64:979-983.
17. Kessler R.C., Nelson C.B., McGonagle K.A., Liu J., Swartz M., Blazer D.G. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996, 17-30.
18. Krause B.J., Prieto C.P., Munoz-Urrutia E., San Martin S., Sobrevia L., Casanello P. Role of arginase-2 and eNOS in the differential vascular reactivity and hypoxia-induced endothelial response in umbilical arteries and veins. Placenta 2012, 33:360-366.
19. Le Melledo J.M., Mahil N., Baker G.B. Nitric oxide: a key player in the relation between cardiovascular disease and major depressive disorder?. JPsychiatry Neurosci 2004, 29:414-416.
20. Mendes Ribeiro A.C., Brunini T.M., Yaqoob M., Aronson J.K., Mann G.E., Ellory J.C. Identification of system y+L as the high-affinity transporter for L-arginine in human platelets: up-regulation of L-arginine influx in uraemia. Pflugers Arch 1999, 438:573-575.
21. Morel-Kopp M.C., McLean L., Chen Q., Tofler G.H., Tennant C., Maddison V., et al. The association of depression with platelet activation: evidence for a treatment effect. JThromb Haemost 2009, 7:573-581.
22. Moreno R.A., Moreno D.H. Escalas de Depressão de Montgomery & Asberg (MADRS) e de Hamilton (HAM-D). Rev Psiquiatr Clínica 1998, 25:262-272.
23. Pereira N.R., Bandeira Moss M., Assumpcao C.R., Cardoso C.B., Mann G.E., Brunini T.M., et al. Oxidative stress, l-arginine-nitric oxide and arginase pathways in platelets from adolescents with anorexia nervosa. Blood Cells Mol Dis 2010, 44:164-168.
24. Pinto V.L., Brunini T.M., Ferraz M.R., Okinga A., Mendes-Ribeiro A.C. Depression and cardiovascular disease: role of nitric oxide. Cardiovasc Hematol Agents Med Chem 2008, 6:142-149.
25. Pinto V.L., de Souza P.F., Brunini T.M., Oliveira M.B., Moss M.B., Siqueira M.A., et al. Low plasma levels of l-arginine, impaired intraplatelet nitric oxide and platelet hyperaggregability: implications for cardiovascular disease in depressive patients. JAffect Disord 2012, 140:187-192.
26. Popa-Wagner A., Mitran S., Sivanesan S., Chang E., Buga A.M. ROS and brain diseases: the good, the bad, and the ugly. Oxid Med Cell Longev 2013, 2013:1-14.
27. Roose S.P. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000, 140:84-88.
28. Roose S.P. Treatment of depression in patients with heart disease. Biol Psychiatry 2003, 54:262-268.
29. Touyz R.M., Briones A.M., Sedeek M., Burger D., Montezano A.C. NOX isoforms and reactive oxygen species in vascular health. Mol Interv 2011, 11:27-35.
30. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
31. Van Holten T.C., Roest M., Riphagen J., Jansen C., Naarding P., Adriaansen H.J., et al. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study. JThromb Haemost 2012, 10:1177-1179.
32. Versteeg H.H., Heemskerk J.W., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiol Rev 2013, 93:327-358.